New use for BladderChek test imminent:
This article was originally published in Clinica
Matritech has moved closer in the US to expanding the use of its 30-minute, doctor's office bladder cancer test, after the FDA deemed the test approvable for helping to diagnose the disease. The NMP22 BladderChek test was cleared last year for monitoring patients previously diagnosed with bladder cancer. Permission for the expanded indication depends on the successful completion of a routine manufacturing facility inspection, which the Newton, Massachusetts firm expects "to be completed promptly".
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.